Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Major Shareholder Acquires $513,000.00 in Stock

Black Diamond Therapeutics, Inc. (NASDAQ:BDTXGet Rating) major shareholder Growth N. V. Biotech acquired 150,000 shares of the company’s stock in a transaction dated Tuesday, April 12th. The shares were bought at an average price of $3.42 per share, for a total transaction of $513,000.00. Following the acquisition, the insider now directly owns 3,885,846 shares of the company’s stock, valued at approximately $13,289,593.32. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

NASDAQ:BDTX opened at $3.41 on Friday. Black Diamond Therapeutics, Inc. has a 52 week low of $2.60 and a 52 week high of $29.02. The firm has a 50-day moving average price of $3.22 and a two-hundred day moving average price of $5.25.

Black Diamond Therapeutics (NASDAQ:BDTXGet Rating) last posted its quarterly earnings data on Thursday, March 17th. The company reported ($0.71) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.01) by $0.30. Equities analysts forecast that Black Diamond Therapeutics, Inc. will post -3.07 earnings per share for the current year.

A number of large investors have recently bought and sold shares of BDTX. Walleye Trading LLC purchased a new stake in Black Diamond Therapeutics in the 4th quarter valued at about $53,000. Cambridge Investment Research Advisors Inc. purchased a new stake in Black Diamond Therapeutics in the 4th quarter valued at about $59,000. AE Wealth Management LLC purchased a new stake in Black Diamond Therapeutics in the 4th quarter valued at about $86,000. Dynamic Technology Lab Private Ltd purchased a new stake in Black Diamond Therapeutics in the 3rd quarter valued at about $87,000. Finally, Invesco Ltd. purchased a new stake in Black Diamond Therapeutics in the 3rd quarter valued at about $90,000. Hedge funds and other institutional investors own 65.74% of the company’s stock.

A number of research firms recently weighed in on BDTX. Zacks Investment Research upgraded shares of Black Diamond Therapeutics from a “hold” rating to a “buy” rating and set a $3.50 target price on the stock in a report on Tuesday, March 22nd. Stifel Nicolaus lowered their target price on shares of Black Diamond Therapeutics from $10.00 to $4.00 and set a “hold” rating on the stock in a report on Friday, March 18th. HC Wainwright lowered shares of Black Diamond Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday, March 22nd. Finally, Wedbush lowered shares of Black Diamond Therapeutics from an “outperform” rating to a “neutral” rating and set a $4.00 target price on the stock. in a report on Tuesday, March 29th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $11.38.

Black Diamond Therapeutics Company Profile (Get Rating)

Black Diamond Therapeutics, Inc, a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations.

Featured Articles

Receive News & Ratings for Black Diamond Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Diamond Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.